메뉴 건너뛰기




Volumn 32, Issue 11, 2007, Pages

Metabolic effects of atypical antipsychotics

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; TIOTIXENE; TRIFLUOPERAZINE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE; ZYPREXIA;

EID: 41149144317     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article
Times cited : (3)

References (40)
  • 1
    • 21244487457 scopus 로고    scopus 로고
    • Modern antipsychotic drugs: A critical overview
    • Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172:1703-1711.
    • (2005) CMAJ , vol.172 , pp. 1703-1711
    • Gardner, D.M.1    Baldessarini, R.J.2    Waraich, P.3
  • 2
    • 1442309143 scopus 로고    scopus 로고
    • Symptoms and circuits, part 3: Schizophrenia
    • Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004;65:8-9.
    • (2004) J Clin Psychiatry , vol.65 , pp. 8-9
    • Stahl, S.M.1
  • 3
    • 0017079279 scopus 로고
    • The dopamine hypothesis of schizophrenia: A review
    • Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2:19-76.
    • (1976) Schizophr Bull , vol.2 , pp. 19-76
    • Meltzer, H.Y.1    Stahl, S.M.2
  • 7
    • 1642283731 scopus 로고    scopus 로고
    • Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Practice Guidelines; Workgroup on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1-56.
    • Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association Practice Guidelines; Workgroup on Schizophrenia. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1-56.
  • 8
    • 11844294731 scopus 로고    scopus 로고
    • Old versus new: Weighing the evidence between the first- and second-generation antipsychotics
    • Davis JM, Chen N. Old versus new: weighing the evidence between the first- and second-generation antipsychotics. Eur Psychiatry. 2005;20:7-14.
    • (2005) Eur Psychiatry , vol.20 , pp. 7-14
    • Davis, J.M.1    Chen, N.2
  • 9
    • 0034025771 scopus 로고    scopus 로고
    • Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double blind PET study of first episode schizophrenia
    • Kapur S, Zipursky RB, Jones C; et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double blind PET study of first episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
    • (2000) Am J Psychiatry , vol.157 , pp. 514-520
    • Kapur, S.1    Zipursky, R.B.2    Jones, C.3
  • 11
    • 48249112499 scopus 로고    scopus 로고
    • Atypical antipsychotics: Mechanism of action
    • Seeman P. Atypical antipsychotics: mechanism of action. Focus. 2004;2:48-58.
    • (2004) Focus , vol.2 , pp. 48-58
    • Seeman, P.1
  • 12
    • 0032982714 scopus 로고    scopus 로고
    • 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
    • 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293.
    • (1999) Am J Psychiatry , vol.156 , pp. 286-293
    • Kapur, S.1    Zipursky, R.B.2    Remington, G.3
  • 13
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of second-generation antipsychotics
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 14
    • 0036886986 scopus 로고    scopus 로고
    • Saftey and tolerability: How do newer generation "atypical" antipsychotics compare?
    • Tandon R. Saftey and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q. 2002; 73:297.
    • (2002) Psychiatr Q , vol.73 , pp. 297
    • Tandon, R.1
  • 15
    • 33646679115 scopus 로고    scopus 로고
    • Metabolic abnormalities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring
    • De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006;21(suppl 2):S11-5.
    • (2006) Int Clin Psychopharmacol , vol.21 , Issue.SUPPL. 2
    • De Hert, M.1    van Eyck, D.2    De Nayer, A.3
  • 16
    • 0001205689 scopus 로고
    • Hyperglycemia and glucosuria following chlorpromazine therapy [letter]
    • Hiles BW. Hyperglycemia and glucosuria following chlorpromazine therapy [letter]. JAMA. 1956;162:1651.
    • (1956) JAMA , vol.162 , pp. 1651
    • Hiles, B.W.1
  • 17
    • 0034795552 scopus 로고    scopus 로고
    • Mechanism of antipsychotic induced weight gain
    • McIntyre RS, et al. Mechanism of antipsychotic induced weight gain. J Clin Psychiatry. 2001;62(suppl 23):23.
    • (2001) J Clin Psychiatry , vol.62 , Issue.SUPPL. 23 , pp. 23
    • McIntyre, R.S.1
  • 18
    • 21544462572 scopus 로고    scopus 로고
    • Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence
    • Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769.
    • (2005) Diabetes Care , vol.28 , pp. 1769
    • Ford, E.S.1
  • 19
    • 33748776056 scopus 로고    scopus 로고
    • Metabolic syndrome and risk of cardiovascular disease: A meta-analysis
    • Galassi, A, Reynolds, K, He, J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812.
    • (2006) Am J Med , vol.119 , pp. 812
    • Galassi, A.1    Reynolds, K.2    He, J.3
  • 20
    • 25144459980 scopus 로고    scopus 로고
    • The metabolic syndrome - a new worldwide definition
    • Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet. 2005;366:1059.
    • (2005) Lancet , vol.366 , pp. 1059
    • Alberti, K.G.1    Zimmet, P.2    Shaw, J.3
  • 21
    • 27744502054 scopus 로고    scopus 로고
    • Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from the NHANES III
    • McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from the NHANES III. Schizophren Res. 2005;80:90-32.
    • (2005) Schizophren Res , vol.80 , pp. 90-32
    • McEvoy, J.P.1    Meyer, J.M.2    Goff, D.C.3
  • 22
    • 4644279733 scopus 로고    scopus 로고
    • Increasing prevalence of the metabolic syndrome among U.S. adults
    • Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27:2444-2449.
    • (2004) Diabetes Care , vol.27 , pp. 2444-2449
    • Ford, E.S.1    Giles, W.H.2    Mokdad, A.H.3
  • 23
    • 34447316519 scopus 로고    scopus 로고
    • Minimising metabolic and cardiovascular risk in schizophrenia: Diabetes, obesity and dyslipidaemia
    • Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007.
    • (2007) J Psychopharmacol
    • Barnett, A.H.1    Mackin, P.2    Chaudhry, I.3
  • 24
    • 0034598111 scopus 로고    scopus 로고
    • Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis
    • Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
    • (2000) BMJ , vol.321 , pp. 1371-1376
    • Geddes, J.1    Freemantle, N.2    Harrison, P.3
  • 25
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of second-generation antipsychotics
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 27
    • 0037349853 scopus 로고    scopus 로고
    • Understanding the new and evolving profile of adverse drug effects in schizophrenia
    • Wirshing DA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Amer. 2003;26:165.
    • (2003) Psychiatr Clin North Amer , vol.26 , pp. 165
    • Wirshing, D.A.1
  • 28
    • 0034042934 scopus 로고    scopus 로고
    • Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
    • Henderon DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
    • (2000) Am J Psychiatry , vol.157 , pp. 975-981
    • Henderon, D.C.1    Cagliero, E.2    Gray, C.3
  • 29
    • 0032751075 scopus 로고    scopus 로고
    • Antipsychotic-induced weight gain: A comprehensive research synthesis
    • Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156:1686.
    • (1999) Am J Psychiatry , vol.156 , pp. 1686
    • Allison, D.B.1    Mentore, J.L.2    Heo, M.3
  • 30
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
    • (2005) N Engl J Med , vol.353 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 31
    • 16644402581 scopus 로고    scopus 로고
    • A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double blind study
    • McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double blind study. J Clin Psychiatry. 2004;65(suppl 18):47-56.
    • (2004) J Clin Psychiatry , vol.65 , Issue.SUPPL. 18 , pp. 47-56
    • McQuade, R.D.1    Stock, E.2    Marcus, R.3
  • 32
    • 0036774640 scopus 로고    scopus 로고
    • Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database
    • Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920.
    • (2002) J Clin Psychiatry , vol.63 , pp. 920
    • Gianfrancesco, F.D.1    Grogg, A.L.2    Mahmoud, R.A.3
  • 33
    • 0344844502 scopus 로고    scopus 로고
    • Relationship of atypical antipsychotics with the development of diabetes
    • Citrome LL, Jaffe AB. Relationship of atypical antipsychotics with the development of diabetes. Ann of Pharmacother. 2003;37:1849-1857.
    • (2003) Ann of Pharmacother , vol.37 , pp. 1849-1857
    • Citrome, L.L.1    Jaffe, A.B.2
  • 34
    • 0036001466 scopus 로고    scopus 로고
    • Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases
    • Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59.
    • (2002) Ann Clin Psychiatry , vol.14 , pp. 59
    • Jin, H.1    Meyer, J.M.2    Jeste, D.V.3
  • 35
    • 33750688606 scopus 로고    scopus 로고
    • Aripirazole versus olanzapine in schizophrenia: A 52 week, open label extension study
    • Presented at: Atlanta, GA;
    • Stock E, Nyilas M, McQuade R, et al. Aripirazole versus olanzapine in schizophrenia: a 52 week, open label extension study. Presented at: APA Annual Meeting; Atlanta, GA; 2005.
    • (2005) APA Annual Meeting
    • Stock, E.1    Nyilas, M.2    McQuade, R.3
  • 36
    • 33749498006 scopus 로고    scopus 로고
    • Hyperlipidemia following treatment with antipsychotic medications
    • Olfson, M, Marcus, SC, Corey-Lisle, P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry. 2006;163:1821.
    • (2006) Am J Psychiatry , vol.163 , pp. 1821
    • Olfson, M.1    Marcus, S.C.2    Corey-Lisle, P.3
  • 37
    • 0842348094 scopus 로고    scopus 로고
    • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601
    • American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
  • 38
    • 0043131961 scopus 로고    scopus 로고
    • A program for managing weight gain associated with atypical antipsychotics
    • Vreeland B, Minsky S, Menza M, et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv. 2003;54:1155-1157.
    • (2003) Psychiatr Serv , vol.54 , pp. 1155-1157
    • Vreeland, B.1    Minsky, S.2    Menza, M.3
  • 39
    • 24944539629 scopus 로고    scopus 로고
    • Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
    • Graham KA, Gu H, Lieberman JA, et al. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry. 2005;162:1744.
    • (2005) Am J Psychiatry , vol.162 , pp. 1744
    • Graham, K.A.1    Gu, H.2    Lieberman, J.A.3
  • 40
    • 21044448639 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain
    • Henderson DC, Copeland PM, Daley TB, et al. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. Am J Psychiatry. 2005;162:954.
    • (2005) Am J Psychiatry , vol.162 , pp. 954
    • Henderson, D.C.1    Copeland, P.M.2    Daley, T.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.